Publications

November 2013 (Revised September 2015)
Supplement

GlaxoSmithKline in China (B)

By: John A. Quelch and Margaret L. Rodriguez

In 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later,... View Details

March 2014 (Revised December 2014)
Case

Vision 2020: Takeda and the Vaccine Business

By: John A. Quelch and Margaret L. Rodriguez

In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003... View Details

Keywords: Health Care; Global; NGO; Public Health; Japan; GSK; Vaccine; Supply Chain; Market Entry; Health; Health Care and Treatment; Trade; Market Entry and Exit; Global Strategy; Health Industry; Pharmaceutical Industry

November 2013
Case

GlaxoSmithKline in China (A)

By: John A. Quelch and Margaret L. Rodriguez

Four GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to... View Details

April 2009
Case

GSK's Acquisition of Sirtris: Independence or Integration?

By: Toby E. Stuart and James Weber

An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details

Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration

September 2013 (Revised February 2016)
Case

GlaxoSmithKline: Sourcing Complex Professional Services

By: Heidi K. Gardner and Silvia Hodges Silverstein

Pharmaceutical company GlaxoSmithKline (GSK) uses an innovative new approach to procuring outside legal counsel: it replaces relationship-based selection and law firms' traditional time-based billing with data-driven decision making and an online reverse auction. In... View Details

Keywords: Legal Industry; Procurement; Professional Service Firms; Pricing; Competition; Change Management; Supply Chain Management; Legal Liability; Business Processes; Legal Services Industry; Pharmaceutical Industry

October 2012
Case

GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)

By: Toby Stuart and James Weber

An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details

Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration

June 2012
Case

GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships

By: Arthur A. Daemmrich and Ian McKown Cornell

Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details

Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Biotechnology Industry; Pharmaceutical Industry; Brazil

May 2005 (Revised April 2010)
Case

GlaxoSmithKline: Reorganizing Drug Discovery (A)

By: Robert S. Huckman and Eli Strick

Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery... View Details

Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Operations; Organizational Structure; Performance Improvement; Research and Development; Pharmaceutical Industry